Tel:
+49 (0)241 95 163 153
Fax:
+49 (0)241 95 163 155
E-Mail:
orders@anticorps-enligne.fr

VHL anticorps (AA 1-213)

VHL Reactivité: Humain, Souris WB, IP, IHC (f) Hôte: Souris Monoclonal Ig32 unconjugated
N° du produit ABIN967508
  • Antigène Voir toutes VHL Anticorps
    VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
    Épitope
    • 16
    • 15
    • 9
    • 5
    • 5
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 1-213
    Reactivité
    • 61
    • 37
    • 35
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    Humain, Souris
    Hôte
    • 65
    • 12
    • 2
    Souris
    Clonalité
    • 70
    • 9
    Monoclonal
    Conjugué
    • 41
    • 5
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    Cet anticorp VHL est non-conjugé
    Application
    • 46
    • 27
    • 26
    • 26
    • 19
    • 17
    • 12
    • 9
    • 6
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunoprecipitation (IP), Immunohistochemistry (Formalin-fixed Sections) (IHC (f))
    Marque
    BD Pharmingen™
     Réactivité croisée
    Souris
    Attributs du produit
    1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
    2. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
    3. Please refer to us for technical protocols.
    Purification
    The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.
    Immunogène
    Human VHL aa. 1-213 Recombinant Protein
    Clone
    Ig32
    Isotype
    IgG1 kappa
    Top Product
    Discover our top product VHL Anticorps primaire
  • Indications d'application
    Western Blot:
    Clone Ig32 is not recommended for Western blot application. It has been shown to recognize a non-specific band above VHL protein. However, RNAi studies have demostrated that clone Ig32 recognizes a fainter band below this dominant band. Also, labs have reported using the 786-O renal cell adenocarcinoma cell line (ATCC CRL-1932, VHL null), siRNA or VHL overexpression to show that clone Ig32 recognizes the VHL protein specifically. Therefore, we recommend using clone Ig32 in over-expressing systems or under native (non-denaturing) conditions such as IHC staining or immunoprecipitation (IP) applications.

    Immunohistochemistry:
    The Ig32 antibody is useful for immunohistochemical staining. Following Retrievagen A pretreatment, purified Ig32 antibody should be used at 2.5 µg/ml to 5 µg/ml and titrated for optimal indirect immunohistochemical staining. Tissues can be visualized via a three-step staining procedure in combination with Biotin Goat anti-Mouse Ig secondary antibody and Streptravidin-HRP together with the DAB Substrate Kit. More conveniently, a Anti-Mouse Ig HRP Detection Kit that contains the biotinylated secondary antibody, antibody diluent, streptavidin-HRP and DAB substrate can be used for staining.
    IP:
    The purified Ig32 antibody has been reported to be useful to immunoprecipitate native human VHL. Please note that this application is not routinely tested. Investigators are advised to determine optimal concentrations for individual applications.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    0.5 mg/mL
    Buffer
    Aqueous buffered solution containing ≤0.09 % sodium azide.
    Agent conservateur
    Sodium azide
    Précaution d'utilisation
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Stock
    4 °C
    Stockage commentaire
    Store undiluted at 4°C.
  • Hsu, Adereth, Kose, Dammai: "Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility." dans: The Journal of biological chemistry, Vol. 281, Issue 17, pp. 12069-80, (2006) (PubMed).

    Qi, Gervais, Li, DeCaprio, Challis, Ohh: "Molecular cloning and characterization of the von Hippel-Lindau-like protein." dans: Molecular cancer research : MCR, Vol. 2, Issue 1, pp. 43-52, (2004) (PubMed).

    Baba, Hirai, Kawakami, Kishida, Sakai, Kaneko, Yao, Shuin, Kubota, Hosaka, Ohno: "Tumor suppressor protein VHL is induced at high cell density and mediates contact inhibition of cell growth." dans: Oncogene, Vol. 20, Issue 22, pp. 2727-36, (2001) (PubMed).

    Iliopoulos, Ohh, Kaelin: "pVHL19 is a biologically active product of the von Hippel-Lindau gene arising from internal translation initiation." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 95, Issue 20, pp. 11661-6, (1998) (PubMed).

    Chen, Kishida, Duh, Renbaum, Orcutt, Schmidt, Zbar: "Suppression of growth of renal carcinoma cells by the von Hippel-Lindau tumor suppressor gene." dans: Cancer research, Vol. 55, Issue 21, pp. 4804-7, (1995) (PubMed).

    Iliopoulos, Kibel, Gray, Kaelin: "Tumour suppression by the human von Hippel-Lindau gene product." dans: Nature medicine, Vol. 1, Issue 8, pp. 822-6, (1995) (PubMed).

    Kibel, Iliopoulos, DeCaprio, Kaelin: "Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C." dans: Science (New York, N.Y.), Vol. 269, Issue 5229, pp. 1444-6, (1995) (PubMed).

  • Antigène
    VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))
    Autre désignation
    VHL (VHL Produits)
    Synonymes
    anticorps HRCA1, anticorps RCA1, anticorps VHL1, anticorps pVHL, anticorps BcDNA:RH61560, anticorps CG13221, anticorps DVhl, anticorps Dmel\\CG13221, anticorps Dvhl, anticorps VHL, anticorps d-VHL, anticorps d-vhl, anticorps dVHL, anticorps dmVHL, anticorps vhl, anticorps rca1, anticorps vhl1, anticorps hrca1, anticorps zgc:158722, anticorps Vhlh, anticorps von Hippel-Lindau tumor suppressor, anticorps von Hippel-Lindau, anticorps von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase, anticorps von Hippel-Lindau disease tumor suppressor, anticorps VHL, anticorps Vhl, anticorps vhl, anticorps CpipJ_CPIJ009992
    Sujet
    The von Hippel-Lindau (VHL) protein is a tumor suppressor that is highly conserved from Drosophila to mammals. VHL protein normally associates with the transcription factor Elongin. Transcription factors typically act in one of three transcriptional stages, initiation, elongation or termination. Elongin functions by increasing the rate of elongation, the rate at which RNA subunits are added to make an RNA transcript longer. Elongin is made up of three subunits, A, B, and C, and each subunit contributes to the function of the whole protein. VHL binds to Elongin B and C subunits, and appears to prevent Elongin A from associating with the B and C subunits, thereby inhibiting the transcriptional activity of Elongin. The ability of VHL to block Elongin function may play a role in normal cell growth regulation. Mutated VHL sequences lose their ability to bind to Elongin subunits B and C, suggesting that the tumor suppression function of VHL may be linked to its ability to bind to Elongin. Likewise, the introduction of wild-type VHL suppresses growth in tumor cell lines lacking normal expression of VHL genes, further supporting a role for VHL in negative growth regulation. The calculated molecular weight of VHL is 24 kDa. However, different migrating species ranging from 21-30 kDa have been observed using antibodies to VHL, and may result from a variety of factors including alternatively spliced VHL mRNAs and protein degradation. This antibody has been reported to recognize both human and mouse VHL.
    Synonyms: von Hippel-Lindau protein, RCA1, HRCA1
    Poids moléculaire
    21-30 kDa
    Pathways
    Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway
Vous êtes ici:
Support technique